Continuous Glucose Monitoring (CGM) – An Evolving Innovation Landscape
Published Date: 12.20.2024
Summary
- Diabetes, particularly Type 2, is a prevalent chronic disease that disrupts the body’s blood sugar regulation, affecting millions globally.
- Traditional monitoring methods, like finger-prick tests, provide limited snapshots of glucose levels, leaving a critical unmet need for ongoing data and personalized insights.
- Continuous Glucose Monitors (CGMs) have revolutionized diabetes management by providing real-time, continuous glucose readings, trends, and alerts, empowering individuals to make informed decisions about diet, exercise, and medication.
- This technology creates a massive market opportunity as the healthcare industry shifts towards preventative health and personalized medicine. Overall, the CGM market is projected to grow significantly, reaching a value of approximately $11.63 billion in 2024 and expanding to $21.32 billion by 2029
Read full report here or download PDF below.
MDB Capital is a wholly-owned subsidiary of MDB Capital Holdings (Nasdaq: MDBH) and a broker-dealer registered with the U.S. Securities and Exchange Commission, a member of FINRA and a member of SIPC. Securities trading, account management, and investment banking services are offered by MDB Capital.
PatentVest, Inc. is a wholly owned subsidiary of MDB Capital Holdings and an affiliated company of MDB Capital.
All patent portfolio data and analysis in this report are based on publicly available information as of December 2024, sourced through PatentVest, our proprietary global patent database. While every effort has been made to ensure accuracy and completeness, the findings may not reflect unpublished, pending, or confidential filings. Companies may hold additional IP assets that are not yet publicly disclosed. This report should be considered a snapshot, not a definitive account, of current IP positions.
Information in this message from employees of MDB Capital or an affiliated company is based upon information that is believed to be reliable. However, neither MDB Capital nor its affiliates warrant its completeness, accuracy or adequacy.
This message is provided for information purposes only. Unless clearly stated, nothing herein shall be construed to be an offer to sell, nor a solicitation of an offer to buy, any financial product. MDB Capital does not make any representations or warranties concerning the past or future performance of any financial instrument. Any trading symbols displayed are for illustrative purposes only and are not intended to portray recommendations.
This message and any attachments are intended only for the use of the addressee and may contain confidential, proprietary and/or privileged information. If you are not the intended recipient, any review, use, distribution, dissemination or copying of this email is prohibited. If you have received this email in error, please notify the sender by replying to this message and delete this email immediately.
To view a listing of all our important disclosures, please visit www.mdb.com/disclosures. For additional information, please visit www.mdb.com or contact us at 945.262.9010.
